Genmab — December 2017
-
Her loves ikke "guidance", men "soft guidance". Denne forskel skal man selvfølgelig forstå og værdsætte! "Soft guidance" må jo være noget der er mindre stringent end "guidance". Han taler osse om at "få noget mere farve på". Igen - han lægger op til en bedre forståelse/kendskab til 2018-tallene, men IKKE en præcis udmelding. Fx - helt hypotetisk - kunne det være at man meldte "til næste år kan vore royalty-indkomster i sig selv dække alle vore udgifter".
-
https://www.fiercepharma.com/pharma/johnson-johnson-scores-big-darzalex-win-first-line-myeloma-slashing-risks-half
“We want it to be fairly universal that you use the drug with whatever regimen you end up choosing,” -
on the Actinium Pharmaceuticals poster https://ir.actiniumpharma.com/press-releases/detail/257/actinium-pharmaceuticals-highlights-promising-data-from-its
-
NJEM Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma http://www.nejm.org/doi/full/10.1056/NEJMoa1714678?query=OF#.Wi_RezcVKJM.twitter=&t=articleDiscussion
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind